Welcome to CDC stacks | Use of BCG vaccines in the control of tuberculosis: a joint statement by the ACIP and the Advisory Committee for Elimination of Tuberculosis - 7356 | Guidelines and Recommendations
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Use of BCG vaccines in the control of tuberculosis: a joint statement by the ACIP and the Advisory Committee for Elimination of Tuberculosis
Filetype[HTML]


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Corporate Authors:
    Centers for Disease Control (U.S.). Immunization Practices Advisory Committee. ; Advisory Committee for the Elimination of Tuberculosis (U.S.) ; Centers for Disease Control (U.S.)
  • Pubmed ID:
    3141765
  • Description:
    Since 1979, when the last Immunization Practices Advisory Committee (ACIP) statement on vaccination with Bacillus of Calmette and Guerin (BCG*) was published, additional data have been published on the epidemiology of tuberculosis (TB) in the United States and on the efficacy of childhood BCG vaccines. As a result, ACIP and the Advisory Committee for Elimination of Tuberculosis have issued the following educational update on BCG vaccines.

    Immunization with BCG vaccine lowers the risk of serious complications of primary TB in children (1-4). However, BCG vaccination should be considered only for children with negative tuberculin skin tests who fall into the following categories: 1) those who cannot be placed on isoniazid preventive therapy but who have continuous exposure to persons with active disease; 2) those with continuous exposure to patients with organisms resistant to isoniazid and rifampin; or 3) those belonging to groups with exceptionally high annual rates of new infection (i.e., greater than 1% per year).

    BCG vaccination is no longer recommended for health-care workers or other adults at high risk for acquiring TB infection. In addition, BCG should not be given to persons who are immunocompromised, including those with human immunodeficiency virus (HIV) infection.

  • Document Type:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like: